Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497817 | 1.00 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| SCHEMBL497818 | 1.00 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| Hydrochloric Acid SCHEMBL7827035 | 0.98 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| Hydrochloric Acid SCHEMBL29221566 | 0.98 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| Hydrochloric Acid SCHEMBL1026469 | 0.98 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| SCHEMBL28499340 | 0.90 | ACP3 (0.51) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| SCHEMBL17441374 | 0.89 | ALDH1A1 (0.56) | SIGMAR1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1997227 | 0.89 | ALDH1A1 (0.56) | SIGMAR1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL24555089 | 0.88 | LTA4H (0.57) | MEN1KMT2ATSHRMEP1BLTA4H | |
| Serine SCHEMBL28178645 | 0.87 | ALPI (0.49) | SIGMAR1MEN1KMT2APOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3790884-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | Astrazeneca AB (SE) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20110124867-A1 | Process and intermediates for the Synthesis of heterocyclic Substituted Piperazines with CXCR3 Antagonist Activity | SCHERING CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124867-A1 | Process and intermediates for the Synthesis of heterocyclic Substituted Piperazines with CXCR3 Antagonist Activity | CXCR3, CXCR5, CCR5 | SIGMAR1 1284/4885MEN1 3553/4885KMT2A 3975/4885 |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | SIGMAR1 249/4885MEN1 1542/4885KMT2A 3307/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | SIGMAR1 260/4885MEN1 1633/4885KMT2A 3492/4885 |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | SIGMAR1 817/4885MEN1 4293/4885KMT2A 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.